Introduced Legislation to Expand Home Infusions for Medicare Patients with Rare Genetic Disease: Introduced the John W. Walsh Alpha-1 Home Infusion Act. This bill will allow Medicare beneficiaries with alpha-1 antitrypsin deficiency to receive essential treatments at home, reducing healthcare costs and enhancing their quality of life.
Expand home infusions for Medicare patients with alpha-1 antitrypsin deficiency.
Occurrences
Evidence
Sponsor: Rep. Salazar, Maria Elvira [R-FL-27] (Introduced 03/25/2025) ... Latest Action: House - 03/25/2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means ... Tracker: Tip | This bill has the status Introduced ... This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency ... coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency.
Assessments
Salazar made a serious federal legislative attempt by sponsoring H.R.2343, the John W. Walsh Alpha-1 Home Infusion Act of 2025, which would provide Medicare coverage for at-home augmentation therapy for qualifying alpha-1 antitrypsin deficiency patients. However, as of the official Congress.gov record checked on May 8, 2026, the bill remains only introduced and referred to House committees, with no passage, enactment, or implemented Medicare coverage expansion. Because the promised policy outcome has not been delivered, but she did materially advance it through sponsorship, this is a failed delivery with an effort badge.